<DOC>
	<DOCNO>NCT02897596</DOCNO>
	<brief_summary>Evaluate efficacy 12 8 week treatment Grazoprevir/Elbasvir Early Chronic Hepatitis C GT1,4 HIV co-infected patient evaluate safety tolerability Grazoprevir + Elbasvir HIV-HCV co-infected patient .</brief_summary>
	<brief_title>Efficacy GZR/EBR Early Chronic Hepatitis C HIV/HCV Co-infected Patients</brief_title>
	<detailed_description>Genotype 1b : 8 week treatment Grazoprevir/Elbasvir Genotype 1a 4 : 12 week treatment Grazoprevir/Elbasvir</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>â‰¥18 year age Patients early chronic hepatitis C ( Genotype 1 4 ) define chronic hepatitis C know episode AHC within last 4 year include fail PEG/RBV never receive therapy AHC . AHC infection diagnose basis document HCVRNA positivity ( &gt; 10.000 IU/mL ) antiHCV seroconversion . No history ascites , bleed esophageal varix , hepatic encephalopathy , signs/symptoms advance liver disease Have liver disease stag assessment follow : Fibroscan perform within 3 previous month Day 1 study show result &lt; 8 kPa Be HIV1 infect , document licensed rapid HIV test confirm licensed Western blot second antibody test method initial rapid HIV and/or E/CIA , HIV1 p24 antigen , plasma HIV1 RNA viral load . Be stable HIV Antiretroviral Therapy ( ART ) least 8 week prior study entry use dual NRTI backbone tenofovir abacavir &lt; 18 year age Patients chronic hepatitis C genotypes 1 4 . History ascites , bleed esophageal varix , hepatic encephalopathy , signs/symptoms advance liver disease Have liver disease stag assessment follow : Fibroscan perform within 3 previous month Day 1 study show result &gt; 8kPa Not HIV1 infect , document licensed rapid HIV test confirm licensed Western blot second antibody test method initial rapid HIV and/or E/CIA , HIV1 p24 antigen , plasma HIV1 RNA viral load . Due know suspected drugdrug interaction , purpose study , use Non Nucleoside Reverse Transcriptase Inhibitors , Inhibitors Protease Inhibitors HIV allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>